Last reviewed 2026-04-20 · How we verify

Meflorin (FENTICLOR)

Phase 2 active Small molecule

Meflorin (generic name: FENTICLOR) is a drug. It is currently in Phase 2 development.

Meflorin works by interacting with a specific biological target to produce a therapeutic effect.

Meflorin, also known as Fenticlor, is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it is not known if it is FDA approved or off-patent. The approved indications for Meflorin are also unknown. Further information on its pharmacokinetics, such as half-life and bioavailability, is not available. As a result, key safety considerations and generic manufacturers are also unknown.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	FENTICLOR
Target	Uracil-DNA glycosylase
Modality	Small molecule
Therapeutic area	Metabolic
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and Meflorin is a key that fits into those locks. When Meflorin binds to its target, it helps to regulate the activity of the cells, which can help to treat certain conditions. This is a simplified explanation, and the actual mechanism may be more complex.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Meflorin CI brief — competitive landscape report
Meflorin updates RSS · CI watch RSS

Frequently asked questions about Meflorin

What is Meflorin?

Meflorin (FENTICLOR) is a Small molecule drug.

How does Meflorin work?

Meflorin works by interacting with a specific biological target to produce a therapeutic effect.

What is the generic name of Meflorin?

FENTICLOR is the generic (nonproprietary) name of Meflorin.

What development phase is Meflorin in?

Meflorin is in Phase 2.

What does Meflorin target?

Meflorin targets Uracil-DNA glycosylase.

Target: All drugs targeting Uracil-DNA glycosylase
Therapeutic area: All drugs in Metabolic

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing